Cut Losses Early, Bet Big Late: The R&D Portfolio Decisions That Separate Pharma Winners from the Rest
Pfizer killed torcetrapib in 2006 after spending $800 million on a cholesterol drug that raised blood pressure instead of lowering […]
Understanding the Rise of Generic Drugs: A Strategic Imperative for the Modern Pharmaceutical Professional
The generic drug industry, often relegated to the background of high-profile blockbuster headlines and breakthrough therapy announcements, is not merely
Dropped Claims Don’t Lie
How Abandoned ANDA Litigation Patents Predict Weaker Enforcement The Most Underrated Signal in Generic Drug Intelligence When a brand pharmaceutical
Dropped Claims Don’t Lie Read Post »
Pharmaceutical Supply Chain Resilience: Lessons from the Pandemic
The pharmaceutical supply chain is a complex, multi-tiered network that historically has been optimized for efficiency and cost reduction above
Pharmaceutical Supply Chain Resilience: Lessons from the Pandemic Read Post »
The 1,825-day head start: How to stop a generic without a patent
Investors and executives often treat the expiration of a composition-of-matter patent as the singular moment of truth in a drug’s
The 1,825-day head start: How to stop a generic without a patent Read Post »
Orange Book vs. Purple Book: Strategic Differences for Small Molecule vs. Biologics Competition
The strategic landscape of the modern pharmaceutical and biotechnology industries is bifurcated by two distinct regulatory and legal architectures that
Decoding the FDA Orange Book’s Therapeutic Equivalence (TE) Codes for Generic Drug Substitution Strategy
The regulatory framework of the United States pharmaceutical industry is governed by a complex interplay of scientific evaluation, legislative compromise,
The Billion-Dollar Blockade: How to Dismantle Drug Patent Thickets and Reclaim the Market
The pharmaceutical landscape in the United States is currently defined by a paradox: a system designed to foster innovation has
The 180-Day Prize: Using Orange Book Patent Data to Secure Early Market Control
Economic success in the generic pharmaceutical industry depends on timing. Between 2026 and 2030, blockbuster drugs representing an estimated $236
The 180-Day Prize: Using Orange Book Patent Data to Secure Early Market Control Read Post »
